NO-Stress. Zwischenfinanzierung/Anbahnung NFP 62
Third-party funded project
Project title NO-Stress. Zwischenfinanzierung/Anbahnung NFP 62
Principal Investigator(s) Müller, Bert
Organisation / Research unit Departement Biomedical Engineering / Biomaterials Science Center (Müller)
Project start 01.09.2009
Probable end 31.12.2009
Status Completed
Abstract Abstract Nanocontainers for local drug delivery to open heart vessels in case of heart attack Atherosclerosis is today?s leading cause of death. We want to provide an effective treatment of this disease by developing nanocontainers which release their cargo of blood vessel opening drugs only at locations where atherosclerotic constriction is present. Background Nanotechnology opens new ways for the targeted control of chemical interactions. In the near future, this will be the basis for the development of drugs that have a specific action on pathologically changed tissue. Such locally acting drugs are now in the process of intensive development in the field of oncology, where a rapidly increasing number of cancer receptors (biomarkers) are being identified. Similar local action approaches for the specific, targeted treatment of constricted heart arteries have not yet been employed to our knowledge. Therefore, we want to use the existing nanotechnology know-how for the development of cardiological drugs to develop new medicinal formulae with specific local action in the field of cardiology for the effective treatment of atherosclerosis and heart attacks. Aim Development of nanocontainers loaded with a cargo of blood vessel opening drugs, which are released locally in response to a specific disease trigger, for the effective local treatment of atherosclerosis at the very place where it can develop into a lethal threat. Significance Today, atherosclerosis is the leading cause of death worldwide. A heart attack is one of its life-threatening consequences. To limit cardiac failure (burden of disease) and mortality during a heart attack, we want to develop a novel treatment based on the local delivery of a vasodilating drug directly to the site of vessel constriction. This should be achieved with the realization of nanocontainers releasing their cargo in response to specific disease triggers at the sites of atherosclerotic vessel constriction. Rapid vessel opening should reestablish sufficient blood flow to limit heart infarction size. In this way, our project could provide a decisive contribution to help fighting a disease to which more patients succumb today world-wide than any other cause of death. Application We will establish an atherosclerotic model with which we will study specific drug delivery under simulated disease conditions. These in-vitro studies will include quantification of the specific disease trigger induced drug release from nanocontainers by fluorescence and chromatography. Once a promising nanocontainer candidate has been identified, a physiological model will be employed to observe the vasodilating effect on real vessels.
Financed by Private Sector / Industry

MCSS v5.8 PRO. 0.392 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |